Retatrutide is getting a lot of attention right now. People are seeing the clinical trial results and asking their doctors about it. So let me give you a straight answer on where things actually stand in Australia.
No. can Australian doctors prescribe retatrutide right now. It has not been approved by the Therapeutic Goods Administration (TGA), which means it sits outside the standard prescribing pathway. But the full picture is more detailed than that, and it matters if you are trying to figure out your options.
What Is Retatrutide and How Does It Work?
Retatrutide is a triple hormone receptor agonist developed by Eli Lilly. It targets three receptors at once, GLP-1, GIP, and glucagon. Most weight loss drugs you have heard of, like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro), hit one or two of those receptors. Retatrutide hits all three. working with a qualified trainer
What that means in practice is stronger appetite suppression, better blood sugar control, and increased energy expenditure. Your body burns more and eats less at the same time.
The Phase 2 trial published in the New England Journal of Medicine in 2023 showed participants lost up to 24.2% of their body weight over 48 weeks at the highest dose. That is a number that made a lot of researchers stop and pay attention. For context, semaglutide at its highest dose produces around 15% weight loss, and tirzepatide gets to around 20-22% in trials.
In my experience looking at the research, the glucagon receptor activation is what separates retatrutide from the pack. Glucagon increases metabolic rate. When you combine that with appetite suppression from GLP-1 and the insulin-sensitising effects of GIP, you get a compounding effect that the dual agonists do not fully replicate.
Is Retatrutide Approved for Use in Australia?
No. As of 2025, retatrutide does not have TGA approval in Australia. It is not listed on the Australian Register of Therapeutic Goods (ARTG). Eli Lilly is currently running Phase 3 trials, which are the large-scale human trials required before any regulatory body will consider approval.
The TGA approval process typically takes 12 to 24 months after a company submits a formal application. That application cannot happen until Phase 3 data is complete and compiled. Phase 3 trials for retatrutide are ongoing, with results expected in late 2025 to 2026.
So realistically, TGA approval is not happening before 2026 at the earliest, and 2027 is a more conservative estimate.
Can Australian Doctors Prescribe Unapproved Medications Like Retatrutide?
This is where it gets interesting. Australia has two legal pathways that allow doctors to prescribe medications that are not TGA-approved.
1. The Special Access Scheme (SAS)
The Special Access Scheme lets doctors apply to the TGA to access unapproved medicines for individual patients. There are three categories. Category B is the most relevant here. It requires the doctor to notify the TGA before prescribing, and it is intended for patients with serious or life-threatening conditions where no suitable approved alternative exists.
The key phrase is “no suitable approved alternative.” Australia already has TGA-approved GLP-1 medications. Ozempic is approved for type 2 diabetes. Wegovy is approved for weight management. Mounjaro (tirzepatide) received TGA approval in 2023. Because these alternatives exist, getting SAS approval for retatrutide would be very difficult to justify on clinical grounds right now.
2. The Authorised Prescriber Scheme
This scheme allows specific doctors to prescribe an unapproved medicine to a class of patients without applying for each individual case. It requires approval from a Human Research Ethics Committee or the TGA itself. This pathway is used more for clinical research settings than general practice.
What I found when looking at how these schemes work in practice is that they are not designed for lifestyle or elective use cases. They exist for patients who have exhausted approved options. A doctor prescribing retatrutide through SAS for general weight loss, when Wegovy and Mounjaro are available, would face serious scrutiny from the TGA and their medical board.
How Does Retatrutide Compare to Weight Loss Drugs Available in Australia Right Now?
Here is a direct comparison based on the best available trial data.
- Semaglutide (Wegovy) produces around 14.9% average body weight loss over 68 weeks in the STEP 1 trial. It is TGA-approved for weight management and available in Australia.
- Tirzepatide (Mounjaro) produces up to 22.5% average body weight loss over 72 weeks in the SURMOUNT-1 trial. TGA-approved in Australia for type 2 diabetes, with weight management approval following.
- Retatrutide produced up to 24.2% average body weight loss over 48 weeks in Phase 2 trials. Not TGA-approved. Not available through standard prescribing.
The difference between tirzepatide and retatrutide in raw weight loss numbers is real but not enormous. What is more interesting is the speed. Retatrutide participants hit significant weight loss faster than the dual agonists in Phase 2 data. Whether that holds in Phase 3 with a larger, more diverse population is the question everyone is waiting on.
In my experience reviewing these trials, the metabolic effects beyond weight loss are what will determine retatrutide’s real-world value. The glucagon component appears to improve liver fat and metabolic markers in ways that GLP-1 alone does not. That could make it particularly useful for people with non-alcoholic fatty liver disease alongside obesity.
What Should Australians Do If They Are Interested in Retatrutide?
Here is the practical answer. You cannot access retatrutide through a standard Australian doctor right now. Trying to source it through compounding pharmacies or overseas suppliers carries serious legal and safety risks. Compounded versions of unapproved drugs are not subject to the same quality controls as TGA-approved medications, and the TGA has issued warnings about this.
What you can do right now is work with what is available and build the foundation that will make any future medication more effective.
- Talk to your GP about approved options. Tirzepatide and semaglutide are available in Australia and produce significant weight loss in clinical trials. If you have a BMI over 30, or over 27 with a weight-related health condition, you may qualify for Wegovy or Mounjaro under current prescribing guidelines.
- Ask about clinical trials. Eli Lilly is running Phase 3 trials for retatrutide. Some of these trials include Australian sites. Participating in a clinical trial is a legal, supervised way to access investigational medications. Check the Australian New Zealand Clinical Trials Registry (ANZCTR) for current openings.
- Build your metabolic health now. This is the part most people skip. GLP-1 medications work significantly better when combined with structured resistance training and adequate protein intake. Research published in Obesity in 2023 showed that people who combined semaglutide with resistance training preserved significantly more lean muscle mass than those who used medication alone. The same principle will apply to retatrutide.
- Work with a qualified coach on your nutrition and training. Medication is a tool. It does not replace the fundamentals. What I saw in the research is that people who enter a GLP-1 or triple agonist protocol with poor muscle mass and no training habit tend to lose a higher proportion of lean tissue, which slows metabolism and makes weight regain more likely after stopping the drug.
When Might Retatrutide Become Available in Australia?
Phase 3 trial data is expected in late 2025 or early 2026. After that, Eli Lilly needs to compile the data and submit a New Drug Application to the FDA in the US. TGA approval in Australia typically follows FDA approval by 12 to 18 months, though the TGA can run parallel reviews.
A realistic timeline for TGA approval and commercial availability in Australia is 2027. That could move earlier if Phase 3 data is strong and Eli Lilly prioritises the Australian market submission, or it could push to 2028 if there are complications.
The question of whether can Australian doctors prescribe retatrutide will have a different answer in two to three years. Right now the answer is no, not through any standard pathway.
FAQ
Is retatrutide legal in Australia?
Retatrutide is not approved by the TGA and is not legally available through standard prescribing. It may be accessible through the Special Access Scheme in very limited circumstances, but this is not a practical pathway for most people.
Can I buy retatrutide online and have it shipped to Australia?
Importing unapproved therapeutic goods into Australia without TGA permission is illegal under the Therapeutic Goods Act 1989. The TGA actively monitors and intercepts such shipments. Beyond the legal risk, unregulated versions of peptide drugs carry serious contamination and dosing risks.
Is retatrutide better than Ozempic?
Based on Phase 2 trial data, retatrutide produces greater weight loss than semaglutide (Ozempic/Wegovy). The average weight loss in the retatrutide Phase 2 trial was higher than what semaglutide produces in its pivotal trials. Phase 3 data will confirm whether this holds at scale.
What is the difference between retatrutide and tirzepatide?
Tirzepatide targets GLP-1 and GIP receptors. Retatrutide targets GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor activation increases energy expenditure, which is why retatrutide shows higher weight loss numbers in early trials.
Should I wait for retatrutide or start treatment now?
Start now if you qualify for approved medications. Waiting two or more years while carrying excess weight has real health costs. Tirzepatide is available in Australia and produces substantial weight loss. You can always transition to retatrutide when it becomes available if your doctor recommends it.
The fundamentals of body composition, resistance training, protein intake, sleep, and stress management matter regardless of which medication you use or whether you use one at all. Building those habits now means you get better results from any intervention, medical or otherwise. Working with a qualified online personal trainer who understands metabolic health and body composition gives you a structured approach that compounds over time, with or without pharmaceutical support.
